Japanese drugmakers are moving to secure drug-discovery assets through corporate venture capital footholds in the United States. Details of the background to local partnerships and specific transactions are available only to subscribers.
Japanese drugmakers are reportedly seeking to secure drug-discovery assets through US corporate venture capital footholds. The focus is on expanding local partnership structures and bringing in drug-discovery assets.
However, the article does not provide details such as the specific companies involved or the timing and scale of the transactions, leaving only limited publicly available information.